# Masitinib in Patients With Symptomatic Mild to Moderate COVID-19

> **NCT05047783** · PHASE2 · UNKNOWN · sponsor: **AB Science** · enrollment: 78 (estimated)

## Conditions studied

- Covid19
- SARS-CoV2 Infection
- Coronavirus Disease 2019

## Interventions

- **DRUG:** Masitinib Mesylate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05047783
- **Lead sponsor:** AB Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-23
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2023-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05047783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05047783, "Masitinib in Patients With Symptomatic Mild to Moderate COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05047783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*